ALNY News and Press, Alnylam Pharmaceuticals Inc. From 02/23/23

Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2022 Earnings Conference Call February 23, 2023, 08:30 AM ET Company Participants Christine Lindenboom - Senior Vice President, Investor Relations and Corporate Communications Yvonne Greenstreet - Chief Executive Officer Tolga Ta...

Alnylam Pharmaceuticals press release ( NASDAQ: ALNY ): Q4 Non-GAAP EPS of -$1.39 beats by $0.09 . Revenue of $335.03M (+29.6% Y/Y) beats by $22.58M . For further details see: Alnylam Pharmaceuticals Non-GAAP EPS of -$1.39 beats by $0.09, revenue of $335.03M beat...

− Achieved Fourth Quarter and Full Year 2022 Global Net Product Revenues of $262 Million and $894 Million, Respectively, Representing 35% Annual Growth Compared to 2021 (43% Using Constant Exchange Rate*) – − Submitted and Received Acceptance of Supplement...

The U.S. Food and Drug Administration (FDA) accepted for review Alnylam Pharmaceuticals' ( NASDAQ: ALNY ) application seeking expanded approval of patisiran to treat cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis. The FDA is expected to make a decision on the supplem...

– PDUFA Date Set for October 8, 2023 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s supplemental New Drug Application...

Summary argenx pre-announced strong Q4 net sales of Vyvgart in early January. The PDUFA date for subcutaneous efgartigimod was pushed back by three months, which means the $98 million Priority Review voucher went to waste. Getting subcutaneous efgartigimod to market is important as ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2022 on Thursday, February 23, 2023, before the U.S. financial markets open. Management will provide...

Summary Regeneron reported preliminary Eylea U.S. net sales in early January that were below expectations. The net sales miss was not driven by increasing pressure from Vabysmo but by a temporary shutdown of a fund that helps with patient copays. Management said they are already see...

Summary Baillie Gifford’s 13F portfolio value decreased from ~$96.99B to ~$95.96B this quarter. They increased NVIDIA, Shopify, NIO Inc., SEA Ltd., Roblox, DoorDash, and Ginkgo Bioworks while reducing Illumina, Ferrari N.V., Arthur J. Gallagher & Co., Albemarle, Meta Platform...

Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperformed in the fourth quarter, dr...